Cellusion

Cellusion Inc.

Basic information

Location (HQ)

Tokyo, JP

Other location(s)

Spinout from

Website

CEO

Established in 

Shin Hatou

2015

Business descriptions

Cellusion always welcomes to join our team as whoever solving global blindness issue together. Regardless of collaboration or investment etc., please feel free to contact us. Why don’t we discuss what we can do together?

Business field

Keywords

Cell therapy

Ophthalmology

Allogeneic

iPSC

TRL

5

Key literatures

To be updated

Company values

Number of filed patents

4

Patent IDs

PCT/JP2012/076048 (JP6041270B2, US9347042B2, EP2765188) , PCT/JP2015/084857 (JP6783446B2, US10501725B2), PCT/JP2018/028654, PCT/JP2019/001142

Total patent value (USD)

Business stage

Series A stage
Series B stage

Types of requested collaborations

R&D Collaboration
Oversea distribution
Investment
Key Opinion Leader (KOL)
Trade sales (M&A)

Ideal exit model

IPO in Japan
Trade sales

Introduction

Cellusion has own IP and technologies to develop and obtain iPS-derived corneal endothelial cells suitable for corneal transplantation to be able to treat thousands of patients from a single batch.

Licensing opportunity

Investment opportunity